181 related articles for article (PubMed ID: 31017696)
1. A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.
Moll JM; Kumagai J; van Royen ME; Teubel WJ; van Soest RJ; French PJ; Homma Y; Jenster G; de Wit R; van Weerden WM
Prostate; 2019 Jun; 79(9):937-948. PubMed ID: 31017696
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.
Yuan X; Cai C; Chen S; Chen S; Yu Z; Balk SP
Oncogene; 2014 May; 33(22):2815-25. PubMed ID: 23752196
[TBL] [Abstract][Full Text] [Related]
3. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
[No Abstract] [Full Text] [Related]
4. Lin28 induces resistance to anti-androgens via promotion of AR splice variant generation.
Tummala R; Nadiminty N; Lou W; Evans CP; Gao AC
Prostate; 2016 Apr; 76(5):445-55. PubMed ID: 26714839
[TBL] [Abstract][Full Text] [Related]
5. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone.
Masoodi KZ; Eisermann K; Yang Z; Dar JA; Pascal LE; Nguyen M; O'Malley K; Parrinello E; Feturi FG; Kenefake AN; Nelson JB; Johnston PA; Wipf P; Wang Z
Endocrinology; 2017 Oct; 158(10):3152-3161. PubMed ID: 28977599
[TBL] [Abstract][Full Text] [Related]
7. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.
Salvi S; Casadio V; Conteduca V; Burgio SL; Menna C; Bianchi E; Rossi L; Carretta E; Masini C; Amadori D; Calistri D; Attard G; De Giorgi U
Br J Cancer; 2015 May; 112(10):1717-24. PubMed ID: 25897673
[TBL] [Abstract][Full Text] [Related]
8. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
[TBL] [Abstract][Full Text] [Related]
9. Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression.
Li H; Xie N; Gleave ME; Dong X
Oncotarget; 2015 Aug; 6(24):20474-84. PubMed ID: 26009876
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer androgen biosynthesis relies solely on CYP17A1 downstream metabolites.
Snaterse G; Taylor AE; Moll JM; O'Neil DM; Teubel WJ; van Weerden WM; Arlt W; Hofland J
J Steroid Biochem Mol Biol; 2024 Feb; 236():106446. PubMed ID: 38104728
[TBL] [Abstract][Full Text] [Related]
11. Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.
Li C; Han X; Yan Q; Ji Y; Zhang R; Yuan D; Yang F; Wang J; Wu M; Zhou J
J Med Chem; 2024 Mar; 67(5):3419-3436. PubMed ID: 38385428
[TBL] [Abstract][Full Text] [Related]
12. Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.
Antonarakis ES; Chandhasin C; Osbourne E; Luo J; Sadar MD; Perabo F
Oncologist; 2016 Dec; 21(12):1427-1435. PubMed ID: 27628492
[TBL] [Abstract][Full Text] [Related]
13. HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.
Almassi N; Reichard C; Li J; Russell C; Perry J; Ryan CJ; Friedlander T; Sharifi N
JAMA Oncol; 2018 Apr; 4(4):554-557. PubMed ID: 29049452
[TBL] [Abstract][Full Text] [Related]
14. Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor.
Cai Y; Chen M; Gong Y; Tang G; Shu Z; Chen J; Zhou H; He Y; Long Z; Gan Y
Clin Transl Med; 2024 Jan; 14(1):e1531. PubMed ID: 38214432
[TBL] [Abstract][Full Text] [Related]
15. Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.
Wang S; Ekoue DN; Raj GV; Kittler R
Cancer Lett; 2018 Dec; 438():86-96. PubMed ID: 30217566
[TBL] [Abstract][Full Text] [Related]
16. Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation.
Simon I; Perales S; Casado-Medina L; Rodríguez-Martínez A; Garrido-Navas MDC; Puche-Sanz I; Diaz-Mochon JJ; Alaminos C; Lupiañez P; Lorente JA; Serrano MJ; Real PJ
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33807106
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone analog inhibits castration-resistant prostate cancer cell growth by inhibiting glycolysis in an AR-dependent manner.
Yu J; Li S; Cheng S; Ahmad M; Chen C; Wan X; Wei S; Pan W; Luo H
J Biol Chem; 2024 Apr; 300(4):107139. PubMed ID: 38447792
[TBL] [Abstract][Full Text] [Related]
18. The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Constantin TA; Varela-Carver A; Greenland KK; de Almeida GS; Olden E; Penfold L; Ang S; Ormrod A; Leach DA; Lai CF; Ainscow EK; Bahl AK; Carling D; Fuchter MJ; Ali S; Bevan CL
Br J Cancer; 2023 Jun; 128(12):2326-2337. PubMed ID: 37076563
[TBL] [Abstract][Full Text] [Related]
19. Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.
Bedoya DJ; Mitsiades N
Onco Targets Ther; 2013; 6():9-18. PubMed ID: 23319868
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.
Alsaidan OA; Onobun E; Ye C; Lou L; Beharry Z; Xie ZR; Lebedyeva I; Crich D; Cai H
Prostate; 2024 Feb; 84(3):254-268. PubMed ID: 37905842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
